Summary
AbbVie Inc.'s Q2 2018 filing shows robust revenue growth, with net revenues increasing by 19.2% year-over-year to $8.3 billion for the quarter and 20.2% to $16.2 billion for the six months. This growth was primarily driven by strong performance in HUMIRA, IMBRUVICA, and the Hepatitis C (HCV) product MAVYRET, which saw significant international expansion. Diluted earnings per share stood at $1.26 for the quarter and $2.99 for the year-to-date. The company demonstrated a strong operational cash flow of $5.5 billion for the first six months, enabling significant capital returns to shareholders through dividends and a substantial $7.5 billion share repurchase program. The report also highlights continued investment in R&D, with over 60 compounds in clinical development, focusing on key areas like immunology, oncology, and neurology, signaling a commitment to future innovation. Financially, AbbVie maintained a solid gross margin of 77% despite a slight year-over-year decrease, attributed to factors like profit sharing and amortization. The company's balance sheet shows total assets of $61.6 billion, with significant intangible assets and goodwill reflecting its business structure. Total liabilities were $58.3 billion, and stockholders' equity (deficit) was negative $3.4 billion, largely due to significant share repurchases and dividend distributions. The company also addressed recent accounting standard adoptions, particularly regarding revenue recognition (ASC 606), with minimal impact on current product sales.
Financial Highlights
52 data points| Revenue | $8.28B |
| Cost of Revenue | $1.93B |
| Gross Profit | $6.34B |
| SG&A Expenses | $1.76B |
| Operating Expenses | $5.52B |
| Operating Income | $2.76B |
| Interest Expense | $320.00M |
| Net Income | $1.98B |
| EPS (Basic) | $1.26 |
| EPS (Diluted) | $1.26 |
| Shares Outstanding (Basic) | 1.57B |
| Shares Outstanding (Diluted) | 1.57B |
Key Highlights
- 1Net revenues grew significantly, up 19.2% year-over-year to $8.3 billion for Q2 2018 and 20.2% to $16.2 billion for the first six months of 2018, driven by key products like HUMIRA, IMBRUVICA, and MAVYRET.
- 2Diluted EPS was $1.26 for the quarter and $2.99 for the six-month period, demonstrating strong earnings performance.
- 3Operating cash flow was robust at $5.5 billion for the first six months of 2018, supporting operations and capital allocation.
- 4AbbVie returned substantial capital to shareholders, including $2.7 billion in dividends and a $7.5 billion share repurchase tender offer completed in June 2018, alongside an additional $1.3 billion in open market repurchases.
- 5The company continues to invest heavily in its R&D pipeline, with over 60 compounds in clinical development, focusing on immunology, oncology, and neurology.
- 6Gross margin remained strong at 77% of net revenues for the quarter, though slightly down from the prior year, reflecting favorable product mix alongside increased amortization and profit-sharing arrangements.
- 7The company adopted new revenue recognition standards (ASC 606) with minimal impact on core product sales revenue.